XT
NVCT icon

XTX Topco’s Nuvectis Pharma NVCT Stock Holding History

XTX Topco’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,066
Closed -$77.8K – 4538
2026
Q1 		$77.8K Buy
+10,066
New +$86.2K ﹤0.01% 3182
2025
Q4 		– Sell
-14,866
Closed -$89.5K – 3646
2025
Q3 		$89.5K Buy
+14,866
New +$102K ﹤0.01% 2047

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

XTX Topco's NVCT Position: Q2 2026 in Review

XTX Topco sold out of Nuvectis Pharma (NVCT) in Q2 2026, closing a stake of 10,066 shares — an estimated $77.8K sold.

XTX Topco first reported a position in NVCT in Q3 2025 and held it in 2 quarters. The position peaked at $89.5K in Q3 2025. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • XTX Topco reported no remaining Nuvectis Pharma position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 10,066 Nuvectis Pharma shares in Q2 2026, an estimated $77.8K.
  • XTX Topco first reported a position in Nuvectis Pharma in Q3 2025 and held it in 2 quarters.
  • XTX Topco's Nuvectis Pharma position peaked at $89.5K in Q3 2025.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.